Dr. Louis Marc Hamer, MD Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 5010 Crenshaw, Suite #100, Pasadena, TX 77505 Phone: 832-399-0399 Fax: 832-399-0398 |
Dr. George Michael Nassif, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3301 Plainview St, Suite #8, Pasadena, TX 77504 Phone: 713-568-8887 Fax: 713-588-8980 |
News Archive
A paper published in the Journal of Biomedical Optics (JBO), "Imaging hydroxyapatite in sub-retinal pigment epithelial deposits by fluorescence lifetime imaging microscopy with tetracycline staining," demonstrates a potential new diagnostic option for catching a degenerative eye disease in its earliest stages.
The U.S. Food and Drug Administration today approved Hiberix, a Haemophilus influenzae Type b (Hib) vaccine, as a booster dose for children 15 months through 4 years old. Hiberix is manufactured by GlaxoSmithKline, with U.S. headquarters in Research Triangle Park, N.C. and Philadelphia.
A collaboration of researchers at Louisiana State University, University of Missouri, and University of Tennessee found that peer victimization is associated with adverse psychological and behavioral problems, including depression and risky health behaviors such as substance use and unprotected sex with multiple partners.
t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of Buerger's Disease. The Company also announced that in a concurrent application in Europe the EMA's Committee for Orphan Medicinal Products recently recommended t2c001 for orphan designation to the European Commission.
The authors analyzed the waxing and waning patterns of reported SARS-CoV-2 cases in all states and provinces in the USA, Mexico, and Canada, and across all counties in the USA.
› Verified 5 days ago